Burkitt lymphoma of the uterus in a human T lymphotropic virus type-1 carrier.
A 71-year-old Japanese woman who was seropositive for T-lymphotropic virus type-1 (HTLV-1) developed primary Burkitt lymphoma of the uterus. CT showed marked enlargement of the uterine body. Chromosomal abnormalities were detected in biopsied cells, and most showed the t (8; 14) (q24; q32) translocation. Fluorescence in situ hybridization (FISH) with a dual-color stain for IgH/C-MYC fusion showed 99% positively. Biopsies from abdominal operation were diagnosed as Burkitt lymphoma. Treatment was started with intensive chemotherapy according to a protocol for Burkitt lymphoma and mature-B cell leukemia. Two regimens were done with four courses with rituximab. Treatment response was fast, with a documented and lasting first complete remission on CT and laboratory markers after the 4 cycle treatment.
Nomura
Shosaku
S
Division of Hematology, Kishiwada City Hospital, Osaka.
Ishii
Kazuyoshi
K
Shimamoto
Yoshiko
Y
Yamamoto
Yoshihisa
Y
Kadota
Eiji
E
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000821:virology*; D019353:Endemic Diseases; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007564:Japan / Q000453:epidemiology; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics / Q000473:pathology; D012074:Remission Induction; D000069283:Rituximab; D016036:Seroepidemiologic Studies; D014178:Translocation, Genetic; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000821:virology*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab